MacroGenics entered into an expanded royalty purchase agreement with Sagard Healthcare Partners for its PD‑1 inhibitor ZYNYZ (retifanlimab). The agreement provides a $60 million upfront payment and up to $20 million in sales‑based milestones tied to global net sales of ZYNYZ.
Under the terms, Sagard will hold a capped royalty interest until it has received either 1.7 times its investment by September 30, 2032, or 2 times its investment at any time thereafter. Once those thresholds are met, the royalty rights revert to MacroGenics.
The transaction extends MacroGenics’ cash runway and supports its strategy of monetizing mature assets to fund early‑stage programs. By securing non‑dilutive capital, the company can invest in its pipeline without issuing additional equity or taking on debt.
The deal underscores MacroGenics’ focus on leveraging the commercial potential of ZYNYZ, which is approved for metastatic or recurrent locally advanced Merkel cell carcinoma. The milestone structure aligns Sagard’s upside with ZYNYZ’s sales performance, providing MacroGenics with upside potential while limiting long‑term royalty obligations.
Analysts view the transaction as a positive step toward strengthening MacroGenics’ balance sheet and accelerating its pipeline development, though the company’s ability to achieve the milestone payments will depend on ZYNYZ’s commercial traction.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.